AURANGABAD: Ranitidine injectible drug were found to be contaminated with a black residue at the Government Medical College and Hospital (GMCH) in Aurangabad, Maharashtra. The medical college had received 80,000 doses in a consignment and administered 20,000 of them to patients between October 10 and November 24, 2018.
GMCH dean Dr Kanan Yelikar said that the inquiry report of the local office of the Food and Drug Administration (FDA) is awaited.
The medical college received the consignment through Haffkine Bio Pharmaceutical Corporation Ltd's centralised drug procurement system on October 10.
While administering the dose in the labour room, doctors noticed black residue in the ampules on November 22.
Over 58,000 doses of Ranitidine drug were recalled till November 29, 2018, said Shivaji Sukr, deputy dean in the college. "The remaining drugs have been used. But, no complaints regarding side-effects have been received so far," he claimed.
The hospital had informed the government, Haffkine and all other government medical colleges and hospitals in the state about the contaminated doses.
Sanjay Kale, FDA joint commissioner, stated that use of the drug has been prohibited in all hospitals of the state. For samples which were sent for analysis, it will take at least 15 days for the report to come following whch further action can be taken, he declared.